{
    "clinical_study": {
        "@rank": "84121", 
        "arm_group": [
            {
                "arm_group_label": "Controls", 
                "description": "Infants born to GBS colonized mother who do not develop GBS disease"
            }, 
            {
                "arm_group_label": "Cases", 
                "description": "Infants with culture confirmed GBS disease"
            }
        ], 
        "brief_summary": {
            "textblock": "Compare anticapsular antibody levels against Group B Streptococcus at delivery in mothers\n      and their infants who develop disease versus those who do not.  Use this comparison to\n      establish antibody levels associated with reductions in risk of GBS disease in infants aged\n      less than 90 days."
        }, 
        "brief_title": "Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Aged Less Than 90 Days", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Invasive Group B Streptococcus Disease", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pregnant women attending participating community/hospital antenatal clinics and/or\n             delivering at participating delivery centers.\n\n          -  Subjects aged \u226518 years.\n\n          -  Able to understand and comply with planned study procedures.\n\n          -  Provides written informed consent.\n\n        Exclusion Criteria:\n\n          -  Refuses to consent to study participation."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Pregnant women aged 18 years or older attending for antenatal care or delivery at 3\n        academic hospital centers in the Johannesburg area and the antenatal clinics serving those\n        hospital centers."
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02099149", 
            "org_study_id": "V98_28OB"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Group B Streptococcus", 
            "early onset disease", 
            "late onset disease", 
            "anticapsular antibodies", 
            "serotype specific"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Soweto", 
                    "country": "South Africa", 
                    "state": "Gauteng", 
                    "zip": "2013"
                }, 
                "name": "Respiratory and Meningeal Pathogen Research Unit"
            }
        }, 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_groups": "2", 
        "official_title": "Establishing a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged Less Than 90 Days.", 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines", 
            "role": "Study Chair"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "South Africa: Medicines Control Council", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Risk of early onset Group B Streptococcus disease (due to serotypes Ia or III) with respect to maternal or newborn anticapsular antibody levels at delivery", 
            "measure": "Early onset Group B Streptococcus Disease due to serotypes Ia or III", 
            "safety_issue": "No", 
            "time_frame": "0-6 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02099149"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Risk of late onset Group B Streptococcus disease (due to serotypes III) with respect to maternal or newborn anticapsular antibody levels at delivery", 
            "measure": "Late onset Group B Streptococcus Disease due to serotype III", 
            "safety_issue": "No", 
            "time_frame": "7-90 days"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}